definiens: ), and Investigational New Drug Applications ( ) for certain formulations containing API, ( as defined be low ) ; and WHEREAS, [COMPANY] has certain process information relating to the synthesis of ECBN - HCl ( as defined below ) and API ; and WHEREAS, [COMPANY] possesses process engineering capabilities and operates process development facilities, which include small scale production an d pilot plants, as well as large scale facilities f or manufacture of commercial quantities of certain ECBN - HCl and AP I ; and WHEREAS, the parties desire to have [COMPANY] evaluate Versic or ’s process information and to scale - up and adapt the current manufacturing process for the preparation of ECBN - HCl and API licensed to Versic or by Lilly to [COMPANY] facilities ; and WHEREAS, [COMPANY] desires to manufacture for [COMPANY] develo pmental, clinical and commercial quantities of ECBN - HCl and API and [COMPANY] desires to purchase from [COMPANY] such quantities